{"id":529,"date":"2016-07-09T06:45:23","date_gmt":"2016-07-09T06:45:23","guid":{"rendered":"https:\/\/blogs.bmj.com\/jnnp\/?p=529"},"modified":"2016-07-16T07:17:26","modified_gmt":"2016-07-16T07:17:26","slug":"neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/","title":{"rendered":"Neuronal autoantibodies as a new enemy in temporal lobe epilepsy"},"content":{"rendered":"<div class=\"mceTemp\"><\/div>\n<p>&nbsp;<\/p>\n<p>In the current issue of JNNP, Vanli-Yavuz and colleagues published the largest systematic screening study of neuronal autoantibodies in mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS). Of relevance to the study, epilepsy is a prevalent neurological disorder affecting over 50 million people worldwide. Despite all the advances in this field, it is estimated that around 30% of all patients with epilepsy are refractory to antiepileptic treatment, MTLE-HS being one of the major causes of intractable epilepsy. Different mechanisms have been related to the development of this disease including a possible autoimmune dysfunction among others.<\/p>\n<p>Returning to the study by Vanli-Yavuz and colleagues, the authors studied the prevalence of different neuronal autoantibodies in a large series of 111 patients with MTLE-HS and compared with 80 control subjects (30 healthy subjects and 50 patient with relapsing-remitting multiple sclerosis) (http:\/\/jnnp.bmj.com\/content\/87\/7\/684.full). Interestingly, they found the presence of neuronal autoantibodies in 22.5% of MTLE-HS patients principally against the VGKC-complex. The healthy and disease control group did not show any neuronal autoantibodies. The presence of neuronal autoantibodies was associated with a history of status epilepticus, diagnosis of psychosis, and involvement of temporal and extra-temporal regions on PET\/SPECT studies. In addition, specifically, the VGKC-complex patient\u2019s subgroup also was associated with cognitive dysfunction. Surprisingly, unexplained remission (either spontaneous or following antiepileptic drugs) was significantly more frequent in the seropositive group (28% vs 3.5%). Finally, the authors reported the absence of inflammatory activity in brain tissue from 7 operated seropositive patients.<\/p>\n<figure id=\"attachment_531\" aria-describedby=\"caption-attachment-531\" style=\"width: 497px\" class=\"wp-caption aligncenter\"><a href=\"https:\/\/blogs.bmj.com\/jnnp\/files\/2016\/07\/Figure-1.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-531\" src=\"https:\/\/blogs.bmj.com\/jnnp\/files\/2016\/07\/Figure-1-300x114.jpg\" alt=\"In this study, approximately one-fourth of the patients showed seropositivity to neuronal autoantibodies, principally against the VGKC-complex.\" width=\"497\" height=\"189\" srcset=\"https:\/\/blogs.bmj.com\/jnnp\/files\/2016\/07\/Figure-1-300x114.jpg 300w, https:\/\/blogs.bmj.com\/jnnp\/files\/2016\/07\/Figure-1-768x292.jpg 768w, https:\/\/blogs.bmj.com\/jnnp\/files\/2016\/07\/Figure-1.jpg 998w\" sizes=\"auto, (max-width: 497px) 100vw, 497px\" \/><\/a><figcaption id=\"caption-attachment-531\" class=\"wp-caption-text\"><strong>Neuronal autoantibodies in mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS).<\/strong> In this study, approximately one-fourth of the patients showed seropositivity to neuronal autoantibodies, principally against the VGKC-complex.<\/figcaption><\/figure>\n<p>&nbsp;<\/p>\n<p>Given the prevalence and the complex treatment approaches to MTLE-HS, the findings in this article seem highly relevant in the future consideration of immunomodulatory therapies in these patients. However, before this can happen, there are still many questions that need to be critically addressed. For instance, What is the role of these neuronal autoantibodies in MTLE-HS pathogenesis? Are they pathogenic or are they the consequence of neuronal destruction? Why are these neuronal autoantibodies associated with patients with unexplained remission?. Clearly, further studies will be needed to answer some of these questions. Nevertheless, this study provides hope to improve our understanding of this disease and suggest a new skyline for this neurological disease.<\/p>\n<p>&nbsp;<\/p>\n<p>Well worth the read!!<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; In the current issue of JNNP, Vanli-Yavuz and colleagues published the largest systematic screening study of neuronal autoantibodies in mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS). Of relevance to the study, epilepsy is a prevalent neurological disorder affecting over 50 million people worldwide. Despite all the advances in this field, it is estimated [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":297,"featured_media":531,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-529","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neuronal autoantibodies as a new enemy in temporal lobe epilepsy - JNNP blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuronal autoantibodies as a new enemy in temporal lobe epilepsy - JNNP blog\" \/>\n<meta property=\"og:description\" content=\"&nbsp; In the current issue of JNNP, Vanli-Yavuz and colleagues published the largest systematic screening study of neuronal autoantibodies in mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS). Of relevance to the study, epilepsy is a prevalent neurological disorder affecting over 50 million people worldwide. Despite all the advances in this field, it is estimated [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/\" \/>\n<meta property=\"og:site_name\" content=\"JNNP blog\" \/>\n<meta property=\"article:published_time\" content=\"2016-07-09T06:45:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2016-07-16T07:17:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/jnnp\/files\/2016\/07\/Figure-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"998\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2016\\\/07\\\/09\\\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2016\\\/07\\\/09\\\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\\\/\"},\"author\":{\"name\":\"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#\\\/schema\\\/person\\\/ae8ff1db7900136065ad542015291a0b\"},\"headline\":\"Neuronal autoantibodies as a new enemy in temporal lobe epilepsy\",\"datePublished\":\"2016-07-09T06:45:23+00:00\",\"dateModified\":\"2016-07-16T07:17:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2016\\\/07\\\/09\\\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\\\/\"},\"wordCount\":406,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2016\\\/07\\\/09\\\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/files\\\/2016\\\/07\\\/Figure-1.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2016\\\/07\\\/09\\\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2016\\\/07\\\/09\\\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2016\\\/07\\\/09\\\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\\\/\",\"name\":\"Neuronal autoantibodies as a new enemy in temporal lobe epilepsy - JNNP blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2016\\\/07\\\/09\\\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2016\\\/07\\\/09\\\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/files\\\/2016\\\/07\\\/Figure-1.jpg\",\"datePublished\":\"2016-07-09T06:45:23+00:00\",\"dateModified\":\"2016-07-16T07:17:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2016\\\/07\\\/09\\\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2016\\\/07\\\/09\\\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2016\\\/07\\\/09\\\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/files\\\/2016\\\/07\\\/Figure-1.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/files\\\/2016\\\/07\\\/Figure-1.jpg\",\"width\":998,\"height\":380,\"caption\":\"In this study, approximately one-fourth of the patients showed seropositivity to neuronal autoantibodies, principally against the VGKC-complex.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2016\\\/07\\\/09\\\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neuronal autoantibodies as a new enemy in temporal lobe epilepsy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/\",\"name\":\"JNNP blog\",\"description\":\"The official JNNP blog. A place to discuss wider neurology beyond the journal&#039;s monthly edition.\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#organization\",\"name\":\"JNNP blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/files\\\/2017\\\/11\\\/blog-logo-jnnp1.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/files\\\/2017\\\/11\\\/blog-logo-jnnp1.png\",\"width\":427,\"height\":34,\"caption\":\"JNNP blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#\\\/schema\\\/person\\\/ae8ff1db7900136065ad542015291a0b\",\"name\":\"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e1b1c0ce10538e3596d7c2c2ee986ea6a4e955673bbe9904c181a4e55a65cc9e?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e1b1c0ce10538e3596d7c2c2ee986ea6a4e955673bbe9904c181a4e55a65cc9e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e1b1c0ce10538e3596d7c2c2ee986ea6a4e955673bbe9904c181a4e55a65cc9e?s=96&d=mm&r=g\",\"caption\":\"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.\"},\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/author\\\/jmatamalacapponi\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neuronal autoantibodies as a new enemy in temporal lobe epilepsy - JNNP blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/","og_locale":"en_US","og_type":"article","og_title":"Neuronal autoantibodies as a new enemy in temporal lobe epilepsy - JNNP blog","og_description":"&nbsp; In the current issue of JNNP, Vanli-Yavuz and colleagues published the largest systematic screening study of neuronal autoantibodies in mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS). Of relevance to the study, epilepsy is a prevalent neurological disorder affecting over 50 million people worldwide. Despite all the advances in this field, it is estimated [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/","og_site_name":"JNNP blog","article_published_time":"2016-07-09T06:45:23+00:00","article_modified_time":"2016-07-16T07:17:26+00:00","og_image":[{"width":998,"height":380,"url":"https:\/\/blogs.bmj.com\/jnnp\/files\/2016\/07\/Figure-1.jpg","type":"image\/jpeg"}],"author":"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/"},"author":{"name":"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.","@id":"https:\/\/blogs.bmj.com\/jnnp\/#\/schema\/person\/ae8ff1db7900136065ad542015291a0b"},"headline":"Neuronal autoantibodies as a new enemy in temporal lobe epilepsy","datePublished":"2016-07-09T06:45:23+00:00","dateModified":"2016-07-16T07:17:26+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/"},"wordCount":406,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jnnp\/files\/2016\/07\/Figure-1.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/","url":"https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/","name":"Neuronal autoantibodies as a new enemy in temporal lobe epilepsy - JNNP blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jnnp\/files\/2016\/07\/Figure-1.jpg","datePublished":"2016-07-09T06:45:23+00:00","dateModified":"2016-07-16T07:17:26+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/#primaryimage","url":"https:\/\/blogs.bmj.com\/jnnp\/files\/2016\/07\/Figure-1.jpg","contentUrl":"https:\/\/blogs.bmj.com\/jnnp\/files\/2016\/07\/Figure-1.jpg","width":998,"height":380,"caption":"In this study, approximately one-fourth of the patients showed seropositivity to neuronal autoantibodies, principally against the VGKC-complex."},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jnnp\/2016\/07\/09\/neuronal-autoantibodies-as-a-new-enemy-in-temporal-lobe-epilepsy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jnnp\/"},{"@type":"ListItem","position":2,"name":"Neuronal autoantibodies as a new enemy in temporal lobe epilepsy"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jnnp\/#website","url":"https:\/\/blogs.bmj.com\/jnnp\/","name":"JNNP blog","description":"The official JNNP blog. A place to discuss wider neurology beyond the journal&#039;s monthly edition.","publisher":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jnnp\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jnnp\/#organization","name":"JNNP blog","url":"https:\/\/blogs.bmj.com\/jnnp\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jnnp\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jnnp\/files\/2017\/11\/blog-logo-jnnp1.png","contentUrl":"https:\/\/blogs.bmj.com\/jnnp\/files\/2017\/11\/blog-logo-jnnp1.png","width":427,"height":34,"caption":"JNNP blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jnnp\/#\/schema\/person\/ae8ff1db7900136065ad542015291a0b","name":"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e1b1c0ce10538e3596d7c2c2ee986ea6a4e955673bbe9904c181a4e55a65cc9e?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e1b1c0ce10538e3596d7c2c2ee986ea6a4e955673bbe9904c181a4e55a65cc9e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e1b1c0ce10538e3596d7c2c2ee986ea6a4e955673bbe9904c181a4e55a65cc9e?s=96&d=mm&r=g","caption":"Dr Jos\u00e9 Manuel Matamala, JNNP web editor."},"url":"https:\/\/blogs.bmj.com\/jnnp\/author\/jmatamalacapponi\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts\/529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/users\/297"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/comments?post=529"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts\/529\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/media\/531"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/media?parent=529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/categories?post=529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/tags?post=529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}